Related Experiment Videos
Evaluation of the InteraX system technology in a high-throughput screening environment
Frank H Büttner1, Renate Kumpf, Susanne Menzel
1Department of Integrated Lead Discovery, Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany. frank.buettner@bc.boehringer-ingelheim.com
Journal of Biomolecular Screening
|August 12, 2005
Summary
Researchers developed a high-throughput screening assay to measure EGFR dimerization, identifying 31 potential inhibitors of this crucial protein-protein interaction. This assay is suitable for discovering small molecules that target dimerization processes.
Area of Science:
- Biochemistry
- Molecular Biology
- Drug Discovery
Background:
- Epidermal Growth Factor Receptor (EGFR) dimerization is a key event in cellular signaling.
- Dysregulated EGFR signaling is implicated in various cancers.
- Developing assays to screen for inhibitors of EGFR dimerization is crucial for targeted cancer therapy.
Purpose of the Study:
- To develop and validate a high-throughput screening (HTS)-compatible cell-based assay for measuring EGFR dimerization.
- To utilize the assay to screen a diverse compound library for inhibitors of EGFR dimerization.
- To assess the HTS capability of the InteraX enzyme complementation technology.
Main Methods:
- Utilized Applied Biosystems' InteraX enzyme complementation technology with chimeric proteins of beta-galactosidase and EGFR.
- Developed a homogeneous 384-well assay for measuring EGFR dimerization upon EGF binding.
- Screened approximately 20,000 diverse compounds in duplicate primary screens.
- Performed hit confirmation and secondary assays to identify true inhibitors and rule out false positives (cytotoxicity, enzyme inhibition).
Main Results:
- Achieved high signal-to-background (S/B) ratios (mean 4.26 and 3.88) and excellent Z' factors (mean 0.74 and 0.71), indicating assay robustness.
- Identified 239 initial hits from the primary screens.
- After confirmation and validation, 31 compounds remained as potential inhibitors of EGFR dimerization or EGF stimulation.
- Ruled out cytotoxicity and direct beta-galactosidase inhibition as mechanisms for the identified compounds.
Conclusions:
- The InteraX enzyme complementation system is a validated HTS-capable technology for monitoring protein-protein interactions like EGFR dimerization.
- The assay successfully identified small molecules capable of inhibiting EGFR dimerization.
- This approach holds promise for the discovery of novel therapeutics targeting protein-protein interaction pathways.